beta-blockers

Description Results NMA

all cause death NaN [NaN; NaN]

all cause death 0.52 [0.30; 0.91]

cardiovascular death 0.41 [0.22; 0.79]

fatal and nonfatal MI 0.85 [0.36; 2.02]

Sudden death 0.69 [0.25; 1.92]

Acebutolol (initial dose intravenously) (n=14)

vs.

control (n=12)

open

Parallel groups

Sample size: 14/12

Primary endpoint:

FU duration: 1 month

Acebutolol 200mg twice daily (n=298)

vs.

placebo (n=309)

Double blind

Parallel groups

Sample size: 298/309

Primary endpoint: death

FU duration: 318 days

all cause death 0.97 [0.72; 1.31]

all cause death 0.51 [0.21; 1.21]

reinfarction 0.90 [0.49; 1.68]

Alprenolol 5-10 mg intravenously, followed by 200 mg twice a day (n=238)

vs.

placebo (n=242)

the 2 stratum <65 et >65 years are grouped together

Double blind

Parallel groups

Sample size: 238/242

Primary endpoint: NA

FU duration: About 1 year

Alprenolol 200mg twice daily (n=114)

vs.

placebo (n=116)

Double blind

Parallel groups

Sample size: 114/116

Primary endpoint: NA (sudden cardiac death may be)

FU duration: 2 years

all cause death 0.95 [0.88; 1.03]

all cause death 0.24 [0.03; 2.06]

all cause death 0.78 [0.52; 1.17]

Atenolol (initial dose intravenously) (n=8037)

vs.

control (n=7990)

No

Sample size: 8037/7990

Primary endpoint:

FU duration: 1 year

Atenolol (n=100)

vs.

(n=94)

Double

Sample size: 100/94

Primary endpoint:

FU duration: 1014 days

Atenolol (initial dose intravenously) (n=244)

vs.

(n=233)

No

Sample size: 244/233

Primary endpoint:

FU duration: 1-4y

all cause death NaN [NaN; NaN]

Betaxolol (n=16)

vs.

(n=15)

Double

Sample size: 16/15

Primary endpoint:

FU duration: 14 days

cardiac event (fatal and non fatal ) 0.55 [0.34; 0.89]

cardiovascular death 0.63 [0.11; 3.67]

fatal and nonfatal MI 0.52 [0.20; 1.32]

cardiac death 0.64 [0.11; 3.73]

reinfarction 0.47 [0.15; 1.50]

Carvedilol target dose 25 mg BID (n=77)

vs.

placebo (n=74)

Patients were subsequently withdrawn if the cardiac enzymes failed to show the typical pattern of acute myocardial necrosis¬

Double blind

Parallel groups

Sample size: 77/74

Primary endpoint: cardiovascular event

FU duration: 6 months

all cause death 1.71 [0.71; 4.14]

Labetalol (initial dose intravenously) (n=83)

vs.

control (n=83)

No

Sample size: 83/83

Primary endpoint:

FU duration: 1 year

all cause death 0.87 [0.69; 1.11]

all cause death 1.04 [0.07; 15.74]

all cause death NaN [NaN; NaN]

all cause death 1.00 [0.51; 1.94]

all cause death 0.64 [0.44; 0.95]

reinfarction 0.65 [0.43; 0.98]

all cause death 0.93 [0.70; 1.23]

cardiovascular death 0.93 [0.69; 1.26]

Sudden death 0.85 [0.48; 1.49]

cardiac death 0.98 [0.72; 1.32]

all cause death 0.58 [0.26; 1.28]

reinfarction 0.55 [0.32; 0.95]

all cause death 0.77 [0.48; 1.24]

Sudden death 0.41 [0.18; 0.93]

all cause death 0.79 [0.55; 1.13]

cardiac death 0.84 [0.57; 1.25]

Metoprolol (initial dose intravenously) (n=2877)

vs.

(n=2901)

Double

Sample size: 2877/2901

Primary endpoint:

FU duration: 15 days

Metoprolol (initial dose intravenously) (n=25)

vs.

(n=26)

Double

Sample size: 25/26

Primary endpoint:

FU duration: 14 days

Practolol, (initial dose intravenously) H87/07, or metoprolol (n=38)

vs.

(n=45)

Double

Sample size: 38/45

Primary endpoint:

FU duration: 1 week

Metoprolol (initial dose intravenously) (15 mg) (n=696)

vs.

(n=694)

No

Sample size: 696/694

Primary endpoint:

FU duration: 5 days

Metoprolol 100mg twice daily (initial dose intravenously) (n=698)

vs.

placebo (n=697)

Double blind

Parallel groups

Sample size: 698/697

Primary endpoint: all cause death

FU duration: 2 years

Metoprolol 100 mg bid (n=1195)

vs.

placebo (n=1200)

treatment continued for up to 1 year

Double blind

Parallel groups

Sample size: 1195/1200

Primary endpoint: all-cause mortality

FU duration: 18 months

Metoprolol 100mg twice daily (n=273)

vs.

placebo (n=280)

Double blind

Parallel groups

Sample size: 273/280

Primary endpoint: NA

FU duration: 1 year

Metoprolol 100mg twice daily (n=154)

vs.

placebo (n=147)

Double blind

Parallel groups

Sample size: 154/147

Primary endpoint: NA

FU duration: 36 months

Metoprolol 100 mg twice daily for one year (initial dose intravenously) (n=416)

vs.

placebo (n=384)

Double blind

Parallel groups

Sample size: 416/384

Primary endpoint: NA

FU duration: 1 year

all cause death 1.38 [0.47; 4.03]

all cause death 1.79 [0.82; 3.92]

all cause death 0.69 [0.29; 1.67]

all cause death 1.41 [0.65; 3.08]

all cause death 1.30 [0.89; 1.91]

cardiovascular death 1.31 [0.88; 1.96]

Sudden death 1.07 [0.62; 1.86]

cardiac death 1.67 [0.90; 3.10]

all cause death 0.48 [0.27; 0.83]

cardiovascular death 0.40 [0.22; 0.74]

fatal and nonfatal MI 0.47 [0.27; 0.79]

reinfarction 0.00 [0.00; NaN]

all cause death 0.93 [0.65; 1.34]

fatal and nonfatal MI 0.87 [0.69; 1.10]

reinfarction 0.86 [0.62; 1.20]

cardiac event (fatal and non fatal ) 0.87 [0.69; 1.10]

Oxprenolol (n=177)

vs.

(n=136)

Double

Sample size: 177/136

Primary endpoint:

FU duration: 8 weeks

Oxprenolol (n=106)

vs.

(n=114)

Unclear

Sample size: 106/114

Primary endpoint:

FU duration: 21 days

Oxprenolol (n=133)

vs.

(n=127)

Double

Sample size: 133/127

Primary endpoint:

FU duration: 20 days

Oxprenolol (n=157)

vs.

(n=158)

Double

Sample size: 157/158

Primary endpoint:

FU duration: 6 weeks

Oxprenolol slow release 160 mg b.i.d. (n=858)

vs.

placebo (n=883)

Double blind

Parallel groups

Sample size: 858/883

Primary endpoint: NA

FU duration: 1 year

Oxprenolol 160mg daily (n=485)

vs.

placebo (n=488)

Double blind

Parallel groups

Sample size: 485/488

Primary endpoint: sudden death

FU duration: 22 months (at least 6mo)

Oxprenolol 40mg twice daily (n=632)

vs.

placebo (n=471)

Double blind

Parallel groups

Sample size: 632/471

Primary endpoint: cardiac event

FU duration: 48 months

all cause death 1.00 [0.06; 15.55]

all cause death 0.97 [0.67; 1.40]

Sudden death 0.91 [0.56; 1.48]

cardiac death 0.94 [0.63; 1.40]

reinfarction 0.93 [0.43; 2.01]

Pindolol (initial dose intravenously) (n=50)

vs.

(n=50)

No

Sample size: 50/50

Primary endpoint:

FU duration: 3 days

Pindolol 15 mg daily (n=263)

vs.

placebo (n=266)

Double blind

Parallel groups

Sample size: 263/266

Primary endpoint: Death

FU duration: 2 years

all cause death 1.57 [0.60; 4.05]

all cause death 1.16 [0.47; 2.86]

all cause death ∞ [NaN; ∞]

all cause death 1.12 [0.62; 2.02]

all cause death 0.82 [0.26; 2.57]

Sudden death 0.57 [0.36; 0.91]

cardiac death 0.75 [0.57; 0.99]

all cause death 0.80 [0.62; 1.02]

reinfarction 0.77 [0.57; 1.04]

Practolol (initial dose intravenously) (n=46)

vs.

(n=48)

No

Sample size: 46/48

Primary endpoint:

FU duration: 7 months

Practolol (initial dose intravenously) then atenolol (n=25)

vs.

(n=29)

Single

Sample size: 25/29

Primary endpoint:

FU duration: 6 months

Practolol (initial dose intravenously) (n=26)

vs.

(n=26)

Unclear

Sample size: 26/26

Primary endpoint:

FU duration: 1 week

Practolol (n=76)

vs.

(n=67)

Unclear

Sample size: 76/67

Primary endpoint:

FU duration: Short term

Practolol (n=72)

vs.

(n=71)

Double

Sample size: 72/71

Primary endpoint:

FU duration: 1 year

Practolol 200mg twice daily (n=1533)

vs.

placebo (n=1520)

Double blind

Parallel groups

Sample size: 1533/1520

Primary endpoint: death, reinfarction

FU duration: 12 months, up to 24 months

all cause death 0.97 [0.52; 1.81]

all cause death 0.75 [0.36; 1.58]

all cause death 0.92 [0.53; 1.58]

all cause death NaN [NaN; NaN]

all cause death 0.80 [0.23; 2.74]

all cause death 0.00 [0.00; NaN]

all cause death NaN [NaN; NaN]

all cause death NaN [NaN; NaN]

all cause death 0.41 [0.11; 1.50]

all cause death 0.67 [0.12; 3.78]

all cause death 2.00 [0.19; 21.06]

all cause death 1.19 [0.59; 2.40]

all cause death NaN [NaN; NaN]

all cause death 1.30 [0.79; 2.15]

all cause death NaN [NaN; NaN]

all cause death 1.09 [0.53; 2.23]

all cause death 0.51 [0.05; 5.44]

all cause death NaN [NaN; NaN]

all cause death 1.21 [0.70; 2.08]

all cause death NaN [NaN; NaN]

all cause death 0.66 [0.17; 2.66]

all cause death 0.73 [0.58; 0.93]

cardiac death 0.71 [0.55; 0.93]

cardiac event (fatal and non fatal ) 0.72 [0.59; 0.89]

reinfarction 0.60 [0.15; 2.43]

all cause death 1.07 [0.64; 1.77]

fatal and nonfatal MI 1.03 [0.51; 2.07]

cardiac death 0.62 [0.33; 1.15]

reinfarction 1.03 [0.51; 2.07]

all cause death 0.74 [0.60; 0.91]

cardiovascular death 0.74 [0.60; 0.93]

cardiac death 0.73 [0.58; 0.91]

reinfarction 0.85 [0.66; 1.10]

Sudden death 0.49 [0.24; 0.98]

fatal and nonfatal MI 1.49 [1.03; 2.18]

all cause death 0.69 [0.42; 1.11]

cardiac death 0.69 [0.47; 1.00]

reinfarction 0.77 [0.41; 1.45]

cardiac event (fatal and non fatal ) 0.73 [0.49; 1.10]

all cause death 0.94 [0.56; 1.58]

cardiovascular death 0.86 [0.50; 1.47]

Propranolol (n=56)

vs.

(n=58)

Double

Sample size: 56/58

Primary endpoint:

FU duration: 28 days

Propranolol (n=52)

vs.

(n=47)

No

Sample size: 52/47

Primary endpoint:

FU duration: 4 weeks

Propranolol (n=66)

vs.

(n=64)

Unclear

Sample size: 66/64

Primary endpoint:

FU duration: 14 days

Propranolol 240mg/d (n=18)

vs.

placebo (n=12)

Double

Sample size: 18/12

Primary endpoint:

FU duration: 3.4 days

Propranolol (n=36)

vs.

(n=36)

No

Sample size: 36/36

Primary endpoint:

FU duration: 36 weeks

Propranolol (n=25)

vs.

(n=25)

Unclear

Sample size: 25/25

Primary endpoint:

FU duration: Unclear

Propranolol (initial dose intravenously) (n=15)

vs.

(n=15)

No

Sample size: 15/15

Primary endpoint:

FU duration: 72 hours

Propranolol (n=16)

vs.

(n=13)

Unclear

Sample size: 16/13

Primary endpoint:

FU duration: 2 days

Propranolol (n=38)

vs.

(n=31)

Double

Sample size: 38/31

Primary endpoint:

FU duration: Up to 35 days

Propranolol (n=40)

vs.

(n=40)

Double

Sample size: 40/40

Primary endpoint:

FU duration: 7 days

Propranolol (initial dose intravenously) (n=35)

vs.

(n=35)

Double

Sample size: 35/35

Primary endpoint:

FU duration: To discharge

Propranolol (n=100)

vs.

(n=95)

Double

Sample size: 100/95

Primary endpoint:

FU duration: 28 days

Propranolol (initial dose intravenously) (n=20)

vs.

(n=20)

Unclear

Sample size: 20/20

Primary endpoint:

FU duration: 1 week

Propranolol (n=226)

vs.

(n=228)

Double

Sample size: 226/228

Primary endpoint:

FU duration: 3 weeks

Propranolol (initial dose intravenously) (n=20)

vs.

(n=23)

No

Sample size: 20/23

Primary endpoint:

FU duration: To discharge

Propranolol (initial dose intravenously) (n=364)

vs.

(n=371)

No

Sample size: 364/371

Primary endpoint:

FU duration: In hospital

Propranolol (initial dose intravenously) (n=47)

vs.

(n=48)

No

Sample size: 47/48

Primary endpoint:

FU duration: To discharge

Propranolol (n=9)

vs.

(n=8)

Double

Sample size: 9/8

Primary endpoint:

FU duration: 14 days

Propranolol (initial dose intravenously) (n=134)

vs.

(n=135)

Single

Sample size: 134/135

Primary endpoint:

FU duration: 36 months

Propranolol (initial dose intravenously) (n=8)

vs.

(n=7)

No

Sample size: 8/7

Primary endpoint:

FU duration: 60 hours

Propranolol (initial dose intravenously) (n=26)

vs.

(n=23)

No

Sample size: 26/23

Primary endpoint:

FU duration: To discharge

Propranolol 30 mg 3 times daily (n=79)

vs.

no propranolol (n=79)

Parallel groups

Sample size: 79/79

Primary endpoint: NA

FU duration: 1 year

Propranolol 40 mg three times a day (n=355)

vs.

placebo (n=365)

Double blind

Parallel groups

Sample size: 355/365

Primary endpoint: NA

FU duration: 9 months

Propranolol 180 or 240 mg/day (n=1916)

vs.

placebo (n=1921)

Double blind

Parallel groups

Sample size: 1916/1921

Primary endpoint: all-cause mortality

FU duration: 25 months

Propranolol 40mg four times a day (n=278)

vs.

placebo (n=282)

Double blind

Parallel groups

Sample size: 278/282

Primary endpoint: NA (sudden cardiac death may be)

FU duration: 1 year

Propranolol 40 mg three times daily(initial dose intravenously) n=132 or atenolol 50 mg twice daily n=127 (n=259)

vs.

placebo (n=129)

Double blind

Parallel groups

Sample size: 259/129

Primary endpoint: NA

FU duration: 1 year

all cause death NaN [NaN; NaN]

Sotalol (initial dose intravenously) (n=15)

vs.

(n=15)

No

Sample size: 15/15

Primary endpoint:

FU duration: 72 hours

all cause death 0.48 [0.05; 4.82]

all cause death ∞ [NaN; ∞]

all cause death 0.73 [0.17; 3.14]

all cause death 0.36 [0.04; 3.36]

all cause death 1.10 [0.07; 16.96]

all cause death 0.79 [0.22; 2.77]

all cause death 0.64 [0.51; 0.81]

cardiovascular death 0.58 [0.45; 0.75]

Sudden death 0.49 [0.35; 0.69]

cardiac death 0.58 [0.45; 0.75]

reinfarction 0.62 [0.48; 0.80]

Timolol (initial dose intravenously) (n=20)

vs.

(n=19)

Unclear

Sample size: 20/19

Primary endpoint:

FU duration: In hospital

Timolol (initial dose intravenously) (n=50)

vs.

(n=50)

Unclear

Sample size: 50/50

Primary endpoint:

FU duration: 28 days

Timolol (initial dose intravenously) (n=73)

vs.

(n=71)

Double

Sample size: 73/71

Primary endpoint:

FU duration: To discharge

Timolol (initial dose intravenously) (n=45)

vs.

(n=49)

Double IV open orally

Sample size: 45/49

Primary endpoint:

FU duration: 28 days

Timolol (n=42)

vs.

(n=46)

Double

Sample size: 42/46

Primary endpoint:

FU duration: 1 year

Timolol (n=56)

vs.

(n=55)

Double

Sample size: 56/55

Primary endpoint:

FU duration: To discharge

Timolol 10mg twice daily (n=945)

vs.

placebo (n=939)

Double blind

Parallel groups

Sample size: 945/939

Primary endpoint: NA

FU duration: 17 months

all cause death NaN [NaN; NaN]

Xamoterol (n=25)

vs.

(n=26)

Double

Sample size: 25/26

Primary endpoint:

FU duration: 7 days

cardiovascular death 0.68 [0.47; 0.98]

death or HF hospitalisation 0.77 [0.61; 0.97]

hospitalisation for heart failure 0.66 [0.49; 0.90]

NYHA improvement 1.42 [1.02; 1.99]

NYHA deterioration 1.18 [0.77; 1.79]

all cause death 0.79 [0.57; 1.10]

all cause death 0.68 [0.56; 0.82]

death or HF hospitalisation 0.83 [0.75; 0.93]

Sudden death 0.58 [0.41; 0.81]

All cause death 0.70 [0.50; 0.98]

bisoprolol 5mg/d (n=320)

vs.

placebo (n=321)

Double blind

Parallel groups

Sample size: 320/321

Primary endpoint: Mortality

FU duration: 1.9 years (range 4-44 mo)

Bisoprolol target dose 10mg/daily (n=1327)

vs.

control (n=1320)

Double blind

Parallel groups

Sample size: 1327/1320

Primary endpoint: all-cause mortality

FU duration: 1.3 years

Trial stop eraly but with a planned follox-up of 24 months

Bisoprolol (n=539)

vs.

placebo (n=0)

Sample size: 539/0

Primary endpoint:

FU duration:

cardiovascular death 0.88 [0.78; 1.00]

hospitalisation for heart failure 0.84 [0.76; 0.92]

all cause death 0.92 [0.82; 1.02]

All cause death 0.70 [0.53; 0.92]

bucindolol titrated to 50mg txice daily (n=1354)

vs.

placebo (n=1354)

Double blind

Parallel groups

Sample size: 1354/1354

Primary endpoint: all-cause mortality

FU duration: 2 years

bucindolol target dose 100mg twice daily (n=12)

vs.

placebo (n=7)

Double blind

Parallel groups

Sample size: 12/7

Primary endpoint: Exercise tolerance, hemodynamics

FU duration: 3 months

bucindolol (n=29)

vs.

placebo (n=29)

Sample size: 29/29

Primary endpoint: Exercise tolerance, hemodynamics

FU duration: 3 mo

bucindolol (n=105)

vs.

placebo (n=34)

Sample size: 105/34

Primary endpoint: Functional class

FU duration: 3 mo

Bucindolol (n=1330)

vs.

placebo (n=0)

Sample size: 1330/0

Primary endpoint:

FU duration:

NYHA deterioration 1.23 [0.77; 1.97]

all cause death 0.77 [0.45; 1.34]

cardiovascular death 0.90 [0.49; 1.66]

death or HF hospitalisation 0.72 [0.49; 1.06]

hospitalisation for heart failure 0.70 [0.43; 1.15]

NYHA improvement 0.94 [0.68; 1.28]

all cause death 0.67 [0.54; 0.83]

death or HF hospitalisation 0.82 [0.74; 0.91]

hospitalisation for heart failure 0.67 [0.59; 0.76]

all cause death 0.78 [0.62; 0.97]

cardiovascular death 0.76 [0.60; 0.96]

death or HF hospitalisation 0.93 [0.83; 1.05]

hospitalisation for heart failure 0.86 [0.69; 1.09]

cardiovascular death 0.70 [0.42; 1.17]

Sudden death 0.87 [0.42; 1.79]

All cause death 0.45 [0.23; 0.86]

All cause death 0.75 [0.57; 0.99]

carvedilol target dose 25mg twice daily (n=207)

vs.

placebo (n=208)

Double blind

Parallel groups

Sample size: 207/208

Primary endpoint: Exercise tolerance, EF Morbidity 1 mortality

FU duration: 19 mo (range 18-24 mo)

carvedilol traget dose of 25 mg twice daily (n=1156)

vs.

placebo (n=1133)

Double blind

Parallel groups

Sample size: 1156/1133

Primary endpoint: all-cause mortality

FU duration: 10.4 months

carvedilol target dose 25mg twice daily (n=975)

vs.

placebo (n=984)

Double blind

Parallel groups

Sample size: 975/984

Primary endpoint: all-cause death or hospitalization

FU duration: 1.3 years

carvedilol (n=20)

vs.

placebo (n=20)

Sample size: 20/20

Primary endpoint: Hemodynamics

FU duration: 4 mo

carvedilol (n=36)

vs.

placebo (n=23)

Sample size: 36/23

Primary endpoint: Hemodynamics

FU duration: 4 mo

carvedilol 25 mg twice daily during 14 weeks (n=33)

vs.

placebo (n=16)

selection of patients tolerating during run-in period 12.5mg twice daily

Sample size: 33/16

Primary endpoint: Hemodynamics

FU duration: 3.5 mo

carvedilol (n=261)

vs.

placebo (n=84)

Double blind

Parallel groups

Sample size: 261/84

Primary endpoint: Exercise tolerance

FU duration: 6.5-8 mo

carvediloltarget dose 25 mg twice daily (n=696)

vs.

placebo (n=398)

nested dose-ranging protocol (6.25, 12.5, 25 mg twice daily) cocnerning 345 patients (32%)

Double blind

Parallel groups

Sample size: 696/398

Primary endpoint: Exercise tolerance

FU duration: 6.5 mo (1 day - 15.1 mo)

carvedilol (n=232)

vs.

placebo (n=134)

Double blind

Parallel groups

Sample size: 232/134

Primary endpoint: progression of heart failure

FU duration: 213 days (0.6 years)

carvedilol (n=70)

vs.

placebo (n=35)

Sample size: 70/35

Primary endpoint: Quality of life

FU duration: <8 mo

Carvedilol (n=554)

vs.

placebo (n=0)

Sample size: 554/0

Primary endpoint:

FU duration:

Carvedilol (n=1102)

vs.

placebo (n=0)

Sample size: 1102/0

Primary endpoint:

FU duration:

all cause death 0.99 [0.49; 2.03]

cardiovascular death 0.92 [0.45; 1.91]

hospitalisation for heart failure 0.75 [0.36; 1.53]

carvedilol (target 25 mg bid) (n=191)

vs.

enalapril (target 10 mg bid) (n=190)

ND

Sample size: 191/190

Primary endpoint: left ventricular remodelling

FU duration: 18 months

all cause death 0.86 [0.78; 0.94]

cardiovascular death 0.82 [0.74; 0.91]

death or HF hospitalisation 0.97 [0.93; 1.01]

carvedilol (target dose 25 mg twice daily) (n=1511)

vs.

metoprolol tartrate target dose 50 mg twice daily (n=1518)

Double blind

Parallel groups

Sample size: 1511/1518

Primary endpoint: all-cause mortality and the composite endpoint

FU duration: 4.83 years

NYHA deterioration 0.87 [0.34; 2.20]

all cause death 1.07 [0.61; 1.86]

death or HF hospitalisation 0.77 [0.56; 1.06]

hospitalisation for heart failure 0.74 [0.50; 1.07]

NYHA improvement 1.26 [0.93; 1.70]

all cause death 0.67 [0.55; 0.82]

cardiovascular death 0.63 [0.51; 0.78]

Sudden death 0.60 [0.46; 0.79]

All cause death 0.91 [0.75; 1.11]

metoprolol target dose 100-150 mg daily (dose divided into two or three per day) (n=194)

vs.

placebo (n=189)

Double blind

Parallel groups

Sample size: 194/189

Primary endpoint: death or transplantation waiting list

FU duration: 18 months

metoprolol CR/XL at target dose of 200 mg once daily (n=1990)

vs.

placebo (n=2001)

Double blind

Parallel groups

Sample size: 1990/2001

Primary endpoint: all-cause death

FU duration: 1 y

metoprolol (n=9)

vs.

placebo (n=16)

Sample size: 9/16

Primary endpoint: Exercise tolerance

FU duration: 12 mo

metoprolol (n=25)

vs.

placebo (n=25)

Sample size: 25/25

Primary endpoint: Exercise tolerance

FU duration: 6 mo

metoprolol (n=15)

vs.

placebo (n=9)

Sample size: 15/9

Primary endpoint: Hemodynamics

FU duration: 3 mo

metoprolol CR 200 mg/d (n=214)

vs.

placebo (n=212)

Double aveugle

Parallel groups

Sample size: 214/212

Primary endpoint:

FU duration: 6 mo

Metoprolol (n=1092)

vs.

placebo (n=0)

Sample size: 1092/0

Primary endpoint:

FU duration:

all cause death ∞ [NaN; ∞]

hospitalisation for heart failure NaN [NaN; NaN]

nebivolol 5mg/d (n=6)

vs.

placebo (n=6)

Double aveugle

Parallel groups

Sample size: 6/6

Primary endpoint: Exercise tolerance

FU duration: 1.5 month

nebivolol (n=11)

vs.

placebo (n=13)

double blind

Parallel groups

Sample size: 11/13

Primary endpoint: Hemodynamics MSI

FU duration: 3 mo

nebivolol (titrated from 1.25 mg once daily to 10 mg once daily) (n=1067)

vs.

placebo (n=1061)

Double blind

Parallel groups

Sample size: 1067/1061

Primary endpoint:

FU duration: 21 months